[Effect of homologous immunoglobulin with normal anti-tissue antibodies on the development of strontium-90-induced osteosarcomas in rats].
In experiments on Wistar rats it was shown that homologous immunoglobulin (a single dose of 25 mg/kg), with normal antitissue antibodies, subcutaneously injected in the following manner: a single injection 90 days or 6 months, or double injection 3 and 6 months after intraperitoneal administration of strontium 90 (11.1 kBq/kg) reduces osteosarcoma occurrence and increases the average lifetime of animals.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D005260:Female; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage*; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000276:immunology / Q000628:therapy*; D012516:Osteosarcoma / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013326:Strontium Radioisotopes / Q000009:adverse effects*
D000888:Antibodies, Anti-Idiotypic; D007136:Immunoglobulins; D013326:Strontium Radioisotopes
Vliianie gomologichnogo immunoglobulina s normal'nymi protivotkanevymi antitelami na razvitie u krys osteosarkom, indutsirovannykh strontsiem-90.